ALK rearrangements are an important target for NSCLC treatment, and patients harboring ALK rearrangements receive significant clinical benefits from ALK tyrosine kinase inhibitors (TKIs) (Shaw et al., 2013). Here, ALK is linked to non-small cell lung carcinoma.